Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q1 2026 earnings summary

25 Aug, 2026

Executive summary

  • Gross revenue for 1Q26 grew 15.8% year-over-year to R$1.57 billion, with retail sales up 15.1% and digital channels reaching 28.5% of retail revenue.

  • Adjusted EBITDA rose 25.6% to R$81.2 million, with margin improving to 5.2%.

  • Adjusted net income increased 38.1% to R$38.5 million, with margin at 2.4%.

  • Market share in the South/Southern Region reached 13.3%, marking the 24th consecutive quarter of gains.

  • Opened 5 new stores and relocated 3, totaling 661 stores at quarter-end.

Financial highlights

  • Retail gross margin held at 29.4%, stable year-over-year.

  • Free cash flow was R$12.4 million, marking the fifth consecutive quarter of positive cash generation.

  • Net debt/EBITDA ratio decreased to 0.88x, the lowest in recent quarters.

  • Consolidated EBITDA (proxy): R$68.2 million, up from R$53.3 million year-over-year.

  • Earnings per share: R$0.22 basic and diluted, up from R$0.17.

Outlook and guidance

  • New growth cycle for 2026–2030 initiated, targeting R$11.5–12 billion in revenue and 950–1,000 stores by 2030.

  • EBITDA margin guidance between 6.7%–7% for the period.

  • Management does not expect material impact from ongoing Brazilian tax reform in 2026.

  • Strategic focus on digitalization, private label expansion, and operational efficiency.

  • Emphasis on store productivity and a balanced financial structure to support the 2030 plan.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more